Who Owns Mounjaro?
Mounjaro is owned by Eli Lilly and Company, a publicly traded American multinational pharmaceutical corporation headquartered in Indianapolis, Indiana. Mounjaro is a tirzepatide injection used to treat type 2 diabetes. Eli Lilly trades on NYSE under ticker LLY.
Parent Company
Eli Lilly and Company
Founded
2022
Status
Publicly Traded
Headquarters
Indianapolis, Indiana, USA
Who Owns Mounjaro?
- Parent Company: Eli Lilly and Company
- Ownership Type: Wholly owned
- Company Type: Publicly Traded
- Stock Ticker: NYSE: LLY
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Mounjaro | Eli Lilly and Company | Wholly owned |
History of Mounjaro
- Founded: 2022
- Founders: Eli Lilly and Company
Mounjaro (tirzepatide) was developed by Eli Lilly through years of research into dual receptor agonism. Unlike earlier GLP-1 receptor agonists such as semaglutide (Ozempic/Wegovy), tirzepatide activates both the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. This dual mechanism of action was hypothesized to provide superior glycemic control and weight loss compared to single GLP-1 receptor agonists.
The pivotal clinical trials for Mounjaro, known as the SURPASS program, demonstrated that tirzepatide provided superior reductions in HbA1c (a measure of blood sugar control) compared to existing diabetes medications including semaglutide. The SURPASS-2 trial, which directly compared tirzepatide to semaglutide 1 mg, showed tirzepatide's superiority in both glycemic control and weight loss.
Mounjaro received FDA approval in May 2022 for the treatment of type 2 diabetes in adults as an adjunct to diet and exercise. The approval was based on the comprehensive SURPASS clinical trial program, which enrolled over 40,000 patients across multiple studies.
The weight loss observed in Mounjaro's clinical trials was extraordinary, with patients losing an average of 15-22% of their body weight depending on the dose, significantly exceeding the weight loss seen with semaglutide. This data generated enormous interest in tirzepatide as a potential obesity treatment, leading Eli Lilly to pursue a separate approval for obesity under the brand name Zepbound.
Zepbound (tirzepatide for obesity) received FDA approval in November 2023, creating a situation where the same active ingredient (tirzepatide) is marketed under two brand names: Mounjaro for diabetes and Zepbound for obesity. This mirrors Novo Nordisk's strategy with semaglutide (Ozempic for diabetes, Wegovy for obesity).
Mounjaro has become one of the fastest-growing pharmaceutical products in history, generating over $5 billion in revenue in 2023 and continuing to grow rapidly in 2024 and 2025 as prescribing expanded and manufacturing capacity increased.
About Eli Lilly and Company
What does Eli Lilly make?
Eli Lilly makes prescription pharmaceuticals across several therapeutic areas. Its most important products are Mounjaro (tirzepatide for type 2 diabetes) and Zepbound (tirzepatide for obesity), which are dual GIP/GLP-1 receptor agonists. The company also makes Verzenio (breast cancer), Trulicity (diabetes), Taltz (psoriasis), Humalog (insulin), and Emgality (migraine).
Is Eli Lilly publicly traded?
Yes, Eli Lilly and Company is listed on NYSE under ticker LLY. Major institutional shareholders include Vanguard Group, BlackRock, and State Street.
Who founded Eli Lilly?
Eli Lilly was founded in 1876 in Indianapolis, Indiana by Colonel Eli Lilly, a Civil War veteran and pharmacist. The company made its first major breakthrough in 1923 when it produced commercial quantities of insulin.
Where is Eli Lilly headquartered?
Eli Lilly is headquartered in Indianapolis, Indiana, USA, where the company was founded in 1876. The company operates research and development centers, manufacturing facilities, and commercial operations in more than 120 countries.
What is Mounjaro and Zepbound?
Mounjaro and Zepbound both contain tirzepatide, a dual GIP/GLP-1 receptor agonist developed by Eli Lilly. Mounjaro is approved for type 2 diabetes, while Zepbound is approved for obesity. Tirzepatide has demonstrated superior efficacy to existing GLP-1 drugs in clinical trials, with patients losing an average of approximately 20% of their body weight in obesity trials.
Who owns Eli Lilly?
Eli Lilly and Company is publicly traded on NYSE with a broad institutional and retail shareholder base. No single shareholder holds a controlling stake. David Ricks serves as Chairman and CEO.
- Founded: 1876
- Headquarters: Indianapolis, Indiana, USA
- Company Type: Publicly Traded
- Stock: NYSE: LLY
Where Is Mounjaro Made / Based?
- Headquarters: Indianapolis, Indiana, USA
- Manufacturing / Operations: United States, Europe
Brands Owned by Eli Lilly and Company
- Zepbound - Prescription weight loss medication brand owned by Eli Lilly, containing tirzepa...
Mounjaro Ownership: Pros & Cons
Advantages
- +Effective treatment for type 2 diabetes management
- +Additional weight loss benefits observed in clinical trials
- +Backed by Eli Lilly's pharmaceutical research and development
- +Strong clinical evidence and FDA approval
- +Growing market demand and adoption
- +Continuous research for expanded indications
Considerations
- -High cost and insurance coverage challenges
- -Potential side effects and contraindications
- -Dependency on Eli Lilly's manufacturing and supply chain
- -Competition from other diabetes medications
- -Regulatory and reimbursement challenges
- -Need for ongoing patient monitoring and management
Frequently Asked Questions About Mounjaro
Competitors to Mounjaro
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Novo Nordisk | Denmark | 2017 | Mass Market | Global | All Genders | |
| Novo Nordisk | Denmark | 2021 | Mass Market | Global | All Genders |
Learn More About Competitors
Ozempic
Owned by Novo Nordisk
Prescription diabetes medication brand owned by Novo Nordisk, containing semaglutide as the active ingredient.
Wegovy
Owned by Novo Nordisk
Prescription weight loss medication brand owned by Novo Nordisk, containing semaglutide as the active ingredient.
Competitive Analysis
Market Positioning: Mounjaro competes with 2 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Eli Lilly and Company Stock Information
Jobs at Eli Lilly and Company
Latest News About Mounjaro
Related Articles About Mounjaro
View more articles
Pharmaceutical Brand Ownership: A Complete Guide
Who makes your medications? Discover which corporations own the biggest pharmaceutical brands, from Ozempic to Tylenol, and how pharma M&A affects you.
The Most Acquired Categories: Tech vs CPG vs Pharma
Which industries see the most brand acquisitions? We compared technology, consumer goods, and pharmaceuticals to find out where the most M&A activity happens and why.
Why Big Pharma Keeps Buying Smaller Drug Brands
AbbVie spent $63 billion on Allergan. Pfizer spent $43 billion on Seagen. Why do pharmaceutical giants keep acquiring smaller companies? The answer lies in the patent cliff.
People Also Searched
Discover popular brands and companies in the pharmaceuticals-healthcare category and related searches from other users.
Ozempic
Prescription diabetes medication brand owned by Novo Nordisk, containing semaglutide as the active ingredient.
Wegovy
Prescription weight loss medication brand owned by Novo Nordisk, containing semaglutide as the active ingredient.
Zepbound
Prescription weight loss medication brand owned by Eli Lilly, containing tirzepatide as the active ingredient.